Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE ER versus FELBATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE ER versus FELBATOL.
DEPAKOTE ER vs FELBATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABAergic activity by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase; blocks voltage-gated sodium and T-type calcium channels; reduces glutamate release.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
500-1000 mg orally once daily; usual maximum dose 60 mg/kg/day.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 10-60 hours); clinical context: extended-release formulation allows once-daily dosing, steady-state achieved in 4-5 days
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Primarily renal (30-50% as glucuronide conjugates, <3% as unchanged drug); minor fecal (10-20%)
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant